Table 2. Continuous peak post-operative biomarker levels according to whether the statin was held or continued prior to surgery.
| Held (n=494) | Continued (n=131) | Estimate (SE) P valuea | ||
|---|---|---|---|---|
| Unadjusted | Adjustedb | |||
| Urine IL-18 (pg/mL) | 103.5 (49.5, 197.7) | 42.9 (21.4, 83.1) | 0.75 (0.12) P<0.0001 | 0.67 (0.12) P<0.0001 |
| Urine NGAL (ng/mL) | 49.9 (24.6, 117.6) | 31.4 (13.7, 58.7) | 0.7 (0.14) P<0.0001 | 0.66 (0.15) P<0.0001 |
| Urine Kim-1 (ng/mL) | 9.3 (5.8, 16) | 5.9 (3.6, 10.5) | 0.49 (0.08) P<0.0001 | 0.42 (0.09) P<0.0001 |
| Plasma NGAL (ng/mL) | 209.9 (148.5, 288.7) | 168.6 (111.6, 252.3) | 0.19 (0.06) P=0.0005 | 0.24 (0.06) P<0.0001 |
| Urine L-FABP (ng/mL) | 38.7 (15.5, 130.6) | 26.8 (8.6, 86.8) | 0.43 (0.15) P=0.004 | 0.39 (0.16) P=0.01 |
| Urine Albumin (mg/L) | 54.9 (31.7, 97.8) | 51.4 (19.3, 93.9) | 0.28 (0.1) P=0.007 | 0.28 (0.11) P=0.009 |
Peak biomarker levels were defined as the highest biomarker value in the first 3 post-operative days
Median (25th percentile, 75th percentile) presented
a
Est (SE) is the estimate and standard error from the linear regression model on log-transformed biomarkers.
b
Adjusted for age, gender, race, diabetes, type of surgery (CABG and valve vs. CABG or valve), pre-operative eGFR (<60, >=60), congestive heart failure, cardiac catheterization, pre-operative urine albumin to creatinine ratio (<10, 10-30, >30), pre-operative ACEi/ARB (yes/no), pre-operative diuretic (yes/no), pre-operative calcium channel blocker (yes/no)